^
    20h
    Chemotherapy and Cadonilimab combined with or without Chidamide as first-line treatment for advanced and metastatic biliary tract cancer (B-Elievable/SCOG-B004): A multi-cohort, exploratory, phase 2trial (ChiCTR2400087443)
    P2, N=78, Recruiting, The First affiliated hospital of Soochow university; The First affiliated hospital of Soochow university | Not yet recruiting --> Recruiting | N=52 --> 78
    Enrollment open • Enrollment change
    |
    gemcitabine • capecitabine • oxaliplatin • Epidaza (chidamide) • Kaitanni (cadonilimab)
    20h
    A Prospective, Cohort, Open Study of Immunoradiotherapy Combined with Cidarbenamide and PD-1 Monotherapy in the Backline Treatment of Advanced Solid Tumors (ChiCTR2300068737)
    P4, N=67, Recruiting, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | N=35 --> 67
    Enrollment open • Phase classification • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Tyvyt (sintilimab) • Epidaza (chidamide)
    1d
    Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial. (PubMed, JAMA)
    MYC/BCL2 double-expressor lymphoma (DEL), a distinct population of DLBCL defined by MYC and BCL2 coexpression, refers to poor prognosis after standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. This trial is the first to demonstrate the benefit of an epigenetic modulator in DLBCL, offering a new first-line therapeutic approach dually targeting MYC and BCL2 oncoprotein for this high-risk population. ClinicalTrials.gov Identifier: NCT04231448.
    Clinical • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    1d
    Chidamide synergizes with cisplatin-etoposide to trigger pyroptosis and anti-tumor immunity in diffuse large B-cell lymphoma. (PubMed, Commun Med (Lond))
    The chidamide-cisplatin-etoposide combination triggers immunogenic pyroptosis via the caspase-3/gasdermin E axis and activates adaptive immunity. This regimen represents a promising therapeutic strategy for relapsed diffuse large B-cell lymphoma warranting clinical investigation.
    Journal
    |
    CD8 (cluster of differentiation 8) • CASP3 (Caspase 3) • GSDME (Gasdermin E)
    |
    cisplatin • etoposide IV • Epidaza (chidamide)
    2d
    SCENT-3: Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Sun Yat-sen University
    New trial
    |
    Tyvyt (sintilimab) • azacitidine • oxaliplatin • Epidaza (chidamide)
    3d
    A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC (clinicaltrials.gov)
    P2, N=118, Completed, Chipscreen Biosciences, Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Epidaza (chidamide)
    3d
    SCREEN: Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Sun Yat-sen University
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Epidaza (chidamide) • Hetronifly (serplulimab)
    8d
    HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial). (PubMed, Signal Transduct Target Ther)
    This trial adopted a Simon two-stage design: eligible patients received tucidinostat plus metronomic capecitabine together with either an aromatase inhibitor (Cohort 1) or fulvestrant (Cohort 2), selected according to prior ET. In addition, exploratory analyses of biomarkers indicated that the baseline TP53 mutation status (Wild type vs. mutated, 7.64 months vs. 3.55 months) and circulating tumor cell (CTC) status (CTC-negative vs. CTC-positive, 7.59 months vs. 3.78 months) were associated with the median PFS. Our study demonstrated that tucidinostat combined with mCAP and ET is efficacious and well-tolerated in patients with HR-positive HER2-negative ABC previously treated with CDK4/6i.
    P2 data • Journal • Circulating tumor cells • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53)
    |
    HER-2 positive • TP53 mutation • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
    |
    capecitabine • fulvestrant • Epidaza (chidamide)
    14d
    Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer. (PubMed, Bioorg Med Chem Lett)
    In this study, we designed and synthesized a series of compounds derived from the histone deacetylase inhibitor (HDACi) Chidamide and the BET bromodomain inhibitor (+)-JQ-1. In the chicken embryo chorioallantoic membrane (CAM) model, 6e inhibited tumor growth and angiogenesis more effectively than chidamide. In summary, 6e demonstrates promising optimization potential as a lead compound for breast cancer therapy.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    JQ-1 • Epidaza (chidamide)
    14d
    ABC-Maint: ABC Maintenance Therapy for AML (clinicaltrials.gov)
    P=N/A, N=104, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    15d
    Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma (clinicaltrials.gov)
    P2, N=34, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Epidaza (chidamide)